FDA has published the USFDA 483 issued to UCB Belgium after an inspection at their facility in April 2023 (Inspectors Hamet M Toure & Alice S.Tsao). The 483 cites use of uncontrolled forms and logbooks, shredded documents in office area, inadequate swab sampling inside RABS for environmental monitoring, deficient operator practices in RABS Read More..